A basal epithelial phenotype is more frequent in interval breast cancers compared with screen detected tumors

被引:160
作者
Collett, K
Stefansson, IM
Eide, J
Braaten, A
Wang, H
Eide, GE
Thoresen, SO
Foulkes, WD
Akslen, LA
机构
[1] Harvard Univ, Sch Med, Childrens Hosp,Vasc Biol Program, Folkman Lab,Karp Family Res Labs 12 125, Boston, MA 02115 USA
[2] Haukeland Hosp, Dept Pathol, Gade Inst, Oslo, Norway
[3] Haukeland Hosp, Dept Radiol, Oslo, Norway
[4] Haukeland Hosp, Clin Res Ctr, Oslo, Norway
[5] Univ Bergen, Dept Publ Hlth & Primary Hlth Care, Bergen, Norway
[6] Canc Registry Norway, Oslo, Norway
[7] McGill Univ, Dept Oncol & Human Genet, Program Canc Genet, Montreal, PQ, Canada
[8] McGill Univ, Dept Med, Montreal, PQ, Canada
关键词
D O I
10.1158/1055-9965.EPI-04-0394
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Interval breast cancer reduce the effectiveness of mammography screening programs. We studied 95 interval cancers, diagnosed during 1996 to 2001 as part of the population-based Norwegian Breast Cancer Screening Program. These cases were matched on size (+/- 2.0 mm) to 95 screen-detected breast cancers, and the tumors were compared by immunohistochemical methods using tissue microarrays. Patients with interval cancers were more likely to be younger [odds ratio (OR), 4.7; P = 0.0001], to have dense breasts (OR, 3.4; P = 0.004), and to have estrogen receptor-negative tumors (OR, 2.6, P = 0.01), and p53 expression was more frequent (OR, 4.0; P = 0.001). Notably, interval cancers were more likely to have a basal epithelial phenotype, in that expression of cytokeratin 5/6 (OR, 2.3; P = 0.04) and P-cadherin (OR, 2.5; P = 0.04) was more frequent in interval cases than in size-matched, screen-detected tumors. In a logistic regression model, p53 expression, age, and breast density were independent predictors of interval cancers. Our data suggest that breast cancers with a basal epithelial phenotype are more likely than nonbasal breast cancers to present between regular mammograms.
引用
收藏
页码:1108 / 1112
页数:5
相关论文
共 49 条
  • [1] Anttinen J, 2003, ANTICANCER RES, V23, P4213
  • [2] TP53 and breast cancer
    Borresen-Dale, AL
    [J]. HUMAN MUTATION, 2003, 21 (03) : 292 - 300
  • [3] Brekelmans CT, 1996, CANCER, V78, P1220, DOI 10.1002/(SICI)1097-0142(19960915)78:6<1220::AID-CNCR8>3.0.CO
  • [4] 2-D
  • [5] Effectiveness of breast cancer surveillance in BRCA1/2 gene mutation carriers and women with high familial risk
    Brekelmans, CTM
    Seynaeve, C
    Bartels, CCM
    Tilanus-Linthorst, MMA
    Meijers-Heijboer, EJ
    Crepin, CMG
    van Geel, AN
    Menke, M
    Verhoog, LC
    van den Ouweland, A
    Obdeijn, IM
    Klijn, JGM
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2001, 19 (04) : 924 - 930
  • [6] Breslow N E, 1980, IARC Sci Publ, P5
  • [7] Screening interval breast cancers: Mammographic features and prognostic factors
    Burrell, HC
    Sibbering, DM
    Wilson, ARM
    Pinder, SE
    Evans, AJ
    Yeoman, LJ
    Elston, CW
    Ellis, IO
    Blamey, RW
    Robertson, JFR
    [J]. RADIOLOGY, 1996, 199 (03) : 811 - 817
  • [8] Molecular classification of breast carcinomas using tissue microarrays
    Callagy, G
    Cattaneo, E
    Daigo, Y
    Happerfield, L
    Bobrow, LG
    Pharoah, PDP
    Caldas, C
    [J]. DIAGNOSTIC MOLECULAR PATHOLOGY, 2003, 12 (01) : 27 - 34
  • [9] Validation of tissue microarray technology in breast carcinoma
    Camp, RL
    Charette, LA
    Rimm, DL
    [J]. LABORATORY INVESTIGATION, 2000, 80 (12) : 1943 - 1949
  • [10] A study of interval breast cancer within the NHS breast screening programme
    Cowan, WK
    Angus, B
    Gray, JC
    Lunt, LG
    Al-Tamimi, SR
    [J]. JOURNAL OF CLINICAL PATHOLOGY, 2000, 53 (02) : 140 - 146